Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines.
The field of tumor vaccination is currently undergoing a shift in focus, from individualized tailor-made vaccines to more generally applicable vaccine formulations. Although primarily predicated by financial and logistic considerations, stemming from a growing awareness that clinical development for wide-scale application can only be achieved through backing from major pharmaceutical companies, these new approaches are also supported by a growing knowledge of the intricacies and minutiae of antigen presentation and effector T-cell activation. Here, the development of whole-cell tumor and dendritic cell (DC)-based vaccines from an individualized autologous set-up to a more widely applicable allogeneic approach will be discussed as reflected by translational studies carried out over the past two decades at our laboratories and clinics in the vrije universiteit medical center (VUmc) in Amsterdam, The Netherlands.
Department of Medical Oncology, Vrije Universiteit medical Center, Amsterdam, The Netherlands.
Tanja D
TD
de Gruijl
Alfons J M
AJ
van den Eertwegh
Herbert M
HM
Pinedo
Rik J
RJ
Scheper
D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003713:Dendritic Cells / Q000276:immunology*; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D009369:Neoplasms / Q000628:therapy*; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous
D019496:Cancer Vaccines